T2 Biosystems, Inc. (TTOO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.5830 |
| Open | 0.5806 |
| Bid | 0.5201 x 1200 |
| Ask | 0.5359 x 1300 |
| Day's Range | 0.5000 - 0.5889 |
| 52 Week Range | 0.5000 - 3.7900 |
| Volume | |
| Avg. Volume | 3,512,200 |
| Market Cap | 87.366M |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3050 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.78 |
Fair Value
Related Research
- T2 Biosystems, Inc.Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.RatingFair ValueEconomic Moat16 days agoArgus Research
- GlobeNewswire
T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Variant
LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant (B.1.1.529). The World Health Organization has designated the Omicron variant as a SARS-CoV-2 “variant of concern” with more than 30 mutations in the spike protein region. The variant was initially identified in South Africa and has already been detected across 20 count
- GlobeNewswire
T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement
LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan. Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments, along with T2Bacteria®, T2Candida® and T2Resistance® Panels through this distributor. The execution of this distribution agreement includes an initial purchase of three T2Dx Instruments
- GlobeNewswire
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present on Thursday, November 18, 2021, at 11:30am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at
